Shortage compounding is not a loophole, Scott explains to Axios

"It is absolutely intentional policy on the part of FDA."

Being a PFM just got better

APC is launching five new benefits for our Pharmacy-Facility members to help you and your business prosper.

Thompson elected, Browning appointed

Two changes to boards of directors were made last week.

Scott predicts ongoing off-and-on shortages

Don't expect brand-name GLP1s to be available long-term, he says

Tenille talks about the cost of firefighters’ lives

The California Board of Pharmacy looked to ban glutathione, but the pushback was hard.

HIPAA, schmipaa — Lilly is at it again

Now Eli Lilly is trying to "convince" people who have used compounded versions of tirzepatide to share their confidential medical records with the company.

Settlement reached in Evexias suit against FDA

A settlement has been reached in a lawsuit brought by Evexias et al against FDA over the agency's 2023 addition of a number of substances to Category 2 of the 503A bulks list.

Rochefort receives Malmberg Award

David Rochefort of Revelation Pharma is this year's recipient of the George and Lucy Malmberg Compounding Advocacy Champion award — APC’s highest honor.

For they’re jolly good Fellows*

This year’s CCH featured the induction of seven new APC fellows.

Be fruitful and multiply … our messaging, that is

Even if you didn't attend Compounders on Capitol Hill, you can multiply the effect of those Hill visits.

APC supports upcoming DEA guidance on constructive transfer

Some good news: DEA is set to issue much-needed new guidance on constructive transfer.

503Bs: FDA has questions, and so do we (do you?)

FDA has requested comments on the challenges and opportunities faced by compounding outsourcing facilities.

Meet our compounding defenders, guardians and champions (Oh my!)

Here’s a big thank you to our Package Deal investors. 

PCAC to discuss 503A bulks list substances

FDA’s Pharmacy Compounding Advisory Committee has announced that it will hold two meetings (!) between now and year-end to consider recommending several bulk drug substances to the 503A Bulks List. 

Welcome, new PFMs!

We’ve added 31 Pharmacy-Facility Members since February!

A quick quote from Scott in WaPo

The Washington Post's story "Eli Lilly ramps up its fight against imitation weight-loss drugs" contains a short quote from CEO Scott Brunner.

CC: August 30, 2024

Cape-free heroes, Lilly’s shell game, and more

Let’s talk about that Lilly announcement

There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats.

Our response to the op-ed in The Hill

The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO.

A new bronze corporate patron

A big welcome to Ro, APC’s newest tier-level corporate patron!

Inside Health Policy quotes Scott (again)

In its article on Lilly's introduction of DTC discounted vials of Zepbound, IHP included a great quote from CEO Scott Brunner.

Scott on Lilly on GLP-1s on CBS

You’ve probably seen the news that Eli Lilly will begin selling Zepbound in vials by mail. What you may have missed is that the CBS News story quoted APC CEO Scott Brunner.

We gave background to Inside Health Policy

Inside Health Policy used APC for information in its piece “Uncertainty Looms Over Bulk Production Of Personalized GLP-1 Drugs.”

Inside Health Policy covers our comment

Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered in detail by Inside Health Policy.

Masoud on ABC News

APC member Masoud Rashidi did a great job defending compounding on ABC News.

Joe Navarra on NBC Nightly News

The story this past Monday is one of the best media reports on compounding we’ve seen.

Compounding post-Chevron

At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.”

503B sourcing: our state-by-state analysis

Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource.

What we’ll be talking about at CCH

When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important. 

‘Hormone Therapy” or “Hormone Replacement Therapy”: What’s the Difference?

By Ashley Berthlot, Director of Marketing, Business Development Specialist, Professional Arts Pharmacy

The term “Hormone Therapy” garners various negative and positive connotations, depending on your background and perspective.… (Read the rest)